 OncLive | Beyond R-CHOP-21: What's New in Diffuse Large B-Cell Lymphoma OncLive The current standard for patients with advanced diffuse large B-cell lymphoma (DLBCL) is R-CHOP-21 (21-day rituximab-cyclophosphamidedoxorubicin- vincristine-prednisone). However, while this regimen cures approximately two-thirds of patients, ... |
